Zobrazeno 1 - 10
of 657
pro vyhledávání: '"Sedarati, F"'
Autor:
Han SN; Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium; Department of Oncology, KU Leuven, Gynaecological Oncology, University Hospitals Leuven, Leuven, Belgium. Electronic address: sileny.han@uzleuven.be., Oza A; Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada., Colombo N; Obstetrics and Gynaecology, University of Milano-Bicocca and European Institute of Oncology IRCCS, Milan, Italy., Oaknin A; Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain., Raspagliesi F; Gynecological Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy., Wenham RM; Department of Gynecologic Oncology, Moffitt Cancer Center, Tampa, FL, USA., Braicu EI; Department for Gynecology Campus Virchow, Charité Medical University Berlin, Berlin, Germany., Jewell A; Obstetrics and Gynecology, University of Kansas Cancer Center, Kansas City, KS, USA., Makker V; Medical Oncology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA., Krell J; Department of Medical Oncology, Imperial College London, London, UK., Alía EMG; Medical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain., Baurain JF; Medical Oncology Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium., Su Z; Computational Biology, Takeda Development Center Americas, Inc., Lexington, MA, USA., Neuwirth R; Biostatistics, Takeda Development Center Americas, Inc., Lexington, MA, USA., Vincent S; Translational Medicine, Takeda Development Center Americas, Inc., Lexington, MA, USA., Sedarati F; Oncology Clinical Research, Takeda Development Center Americas, Inc., Lexington, MA, USA., Faller DV; Oncology Clinical Research, Takeda Development Center Americas, Inc., Lexington, MA, USA., Scambia G; Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Catholic University of the Sacred Heart School of Medicine, Rome, Italy.
Publikováno v:
Gynecologic oncology [Gynecol Oncol] 2023 Nov; Vol. 178, pp. 110-118. Date of Electronic Publication: 2023 Oct 14.
Autor:
Zhou X; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA. xiaofei.zhou@takeda.com., Vaishampayan U; Karmanos Cancer Institute, Detroit, MI, USA.; University of Michigan, Ann Arbor, MI, USA., Mahalingam D; Northwestern Medical Group, Chicago, IL, USA., Harvey RD; Emory University, Atlanta, GA, USA., Chung KY; Prisma Health Cancer Institute/ITOR, Greenville, SC, USA., Sedarati F; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Dong C; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Faller DV; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Venkatakrishnan K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.; EMD Serono Research & Development Institute, Inc., MB, Billerica, USA., Gupta N; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2022 Oct; Vol. 40 (5), pp. 1042-1050. Date of Electronic Publication: 2022 Aug 06.
Autor:
Voss M, Gordon M, Mita M, Rini B, Makker V, Macarulla T, Smith D, Cervantes A, Puzanov I, Pili R, Wang D, Jalal S, Pant S, Patel M, Neuwirth R, Enke A, Shou Y, Sedarati F, Faller D, Burris H
Publikováno v:
BRITISH JOURNAL OF CANCER
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Background This Phase 1 dose-escalation/expansion study assessed safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in advanced solid tumours. Methods Eligible patients received increasing sapanisertib doses on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::3cd2f479360b3bf2c4ae13e196897a9a
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15559
https://www.fundanet.incliva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15559
Autor:
Choueiri TK; Dana-Farber Cancer Institute, Boston, MA, USA., Porta C; University of Pavia and IRCCS San Matteo University Hospital Foundation, Pavia, Italy., Suárez C; Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d´Hebron, Vall d´Hebron Barcelona Hospital Campus, Barcelona, Spain., Hainsworth J; Sarah Cannon Research Institute, Nashville, TN, USA., Voog E; Centre Jean Bernard/Clinique Victor Hugo, Institut Inter-régional de Cancérologie, Le Mans, France., Duran I; Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain., Reeves J; Florida Cancer Specialists/Sarah Cannon Research Institute, Fort Myers, FL, USA., Czaykowski P; CancerCare Manitoba, Winnipeg, Manitoba, Canada., Castellano D; i+12 Research Institute, Hospital Universitario 12 de Octubre, Madrid, Spain., Chen J; Takeda Development Center Americas, Inc., Lexington, MA, USA., Sedarati F; Takeda Development Center Americas, Inc., Lexington, MA, USA., Powles T; Barts Cancer Institute, Royal Free NHS Trust, St. Bartholomew's Hospital, London, UK.
Publikováno v:
The oncologist [Oncologist] 2022 Dec 09; Vol. 27 (12), pp. 1048-1057.
Autor:
Bolleddula J; Takeda Development Center Americas, Inc., Lexington, Massachusetts swapan@bostonpharmaceuticals.com bolleddulajp@yahoo.com., Chen H; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Cohen L; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Zhou X; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Pusalkar S; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Berger A; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Sedarati F; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Venkatakrishnan K; Takeda Development Center Americas, Inc., Lexington, Massachusetts., Chowdhury SK; Takeda Development Center Americas, Inc., Lexington, Massachusetts swapan@bostonpharmaceuticals.com bolleddulajp@yahoo.com.
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2022 Jul; Vol. 50 (7), pp. 989-997. Date of Electronic Publication: 2022 May 03.
Autor:
Handa H; National University Corporation, Gunma University, Maebashi, Japan., Cheong JW; Severence Hospital, Yonsei University Health System, Seoul, South Korea., Onishi Y; National University, Corporation Tohoku University, Sendai, Japan., Iida H; National Hospital Organization Nagoya Medical Center, Nagoya, Japan., Kobayashi Y; International University of Health and Welfare, Mita Hospital, Tokyo, Japan., Kim HJ; Chonnam National University, Hwasun Hospital, Hwasun, South Korea., Chiou TJ; Taipei Municipal Wanfang Hospital, Taipei Medical University, Taipei Veterans General Hospital, Taipei, Taiwan., Izutsu K; National Cancer Center Hospital, Tokyo, Japan., Tsukurov O; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Zhou X; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Faessel H; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Yuan Y; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Sedarati F; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Faller DV; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA., Kimura A; Takeda Pharmaceutical Company Limited, Osaka, Japan., Wu SJ; Division of Hematology, Department of Internal Medicine, Zhongzheng Dist, National Taiwan University Hospital, No.7, Zhongshan S. Rd., Taipei City, 100, Taiwan. wushangju@ntu.edu.tw.
Publikováno v:
Journal of hematology & oncology [J Hematol Oncol] 2022 May 11; Vol. 15 (1), pp. 56. Date of Electronic Publication: 2022 May 11.
Autor:
Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. tosshimi@ncc.go.jp., Kuboki Y; National Cancer Center Hospital East, Chiba, Japan., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yanai T; Takeda Pharmaceutical Company Limited, Osaka, Japan., Faller DV; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Dobler L; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Gupta N; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Sedarati F; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Kim KP; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Publikováno v:
Targeted oncology [Target Oncol] 2022 May; Vol. 17 (3), pp. 377.
Publikováno v:
Science, 1986 Nov 01. 234(4777), 746-748.
Externí odkaz:
https://www.jstor.org/stable/1697944
Autor:
Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan. tosshimi@ncc.go.jp., Kuboki Y; National Cancer Center Hospital East, Chiba, Japan., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Yonemori K; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan., Yanai T; Takeda Pharmaceutical Company Limited, Osaka, Japan., Faller DV; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Dobler L; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Gupta N; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Sedarati F; Millennium Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Kim KP; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Publikováno v:
Targeted oncology [Target Oncol] 2022 Jan; Vol. 17 (1), pp. 15-24. Date of Electronic Publication: 2021 Nov 29.
Autor:
Zhou X; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Friedlander S; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Kupperman E; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Sedarati F; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Kuroda S; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Hua Z; Alnylam Pharmaceuticals Inc., Cambridge, MA, USA., Yuan Y; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Yamamoto Y; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Faller DV; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Haikawa K; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Nakai K; Takeda Pharmaceutical Company Limited, Tokyo, Japan., Bowen S; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA., Dai Y; Takeda Pharmaceutical Company Limited, Beijing, China., Venkatakrishnan K; Millennium Pharmaceuticals, Inc. (a wholly owned subsidiary of Takeda Pharmaceutical Company Limited), Cambridge, MA, USA.
Publikováno v:
Clinical and translational science [Clin Transl Sci] 2021 May; Vol. 14 (3), pp. 1069-1081. Date of Electronic Publication: 2021 Feb 02.